L J Dordelly's research while affiliated with Phoenix VA Health Care System and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (13)
COPD is a debilitating disease with increasing mortality worldwide. The BODE index evaluates disease severity and the St George's Respiratory Questionnaire (SGRQ) measures health status.
To identify the relationship between BODE index and the SGRQ and to test the predictive value of both tools against survival.
Open cohort study of 1398 COPD patien...
Little is known about survival and clinical prognostic factors in females with chronic obstructive pulmonary disease (COPD). The aim of the present study was to determine the survival difference between males and females with COPD and to compare the value of the different prognostic factors for the disease. In total, 265 females and 272 males with...
Peak oxygen uptake (V'(O(2))) remains the gold standard measurement of exercise capacity and has been associated with survival. A modified BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index replacing the 6-min walk distance (6MWD) with V'(O(2)) as % predicted (mBODE%) has been developed and found to have excellent correl...
Exercise impairment as measured by the 6-min walk distance (6MWD) test afflicts many patients with chronic obstructive pulmonary disease (COPD) and is known to predict mortality. Reference equations for the 6MWD in adults have been published but not yet validated. The present authors prospectively followed 1,379 COPD patients for 55+/-30 months and...
In patients with COPD, the maximal oxygen uptake (Vo2) measured at peak exercise and the 6-min walk distance (6MWD) have been associated with survival; however, no study has compared the strength of the association in the same patients. In this study, we compared the association between the 6MWD and peak Vo2 and mortality in 365 patients with COPD....
Haemoglobin (Hb) abnormalities in chronic obstructive pulmonary disease (COPD) are not well characterised. The present authors investigated the prevalence and association of abnormal Hb with clinical outcomes. Analysis of a prospective cohort of stable COPD outpatients (n = 683) in a USA Veterans Administration pulmonary clinic was undertaken. Pati...
The 6-min walking distance (6MWD) test is used in clinical practice and research into patients with chronic obstructive pulmonary disease (COPD). However, little is known about natural long-term change in this parameter. The 6MWD was measured at baseline and then annually for 5 yrs in 294 patients with COPD and its annual rate of decline was determ...
Frequent exacerbations are associated with a faster decline in FEV(1), impaired health status, and worse survival. Their impact and temporal relationship with other outcomes such as functional status, dyspnea, and the multidimensional body mass index, obstruction, dyspnea, exercise capacity (BODE) index remain unknown.
We reasoned that exacerbation...
Citations
... • COPD lung function decline is accelerated by exacerbations. The impact of exacerbations was simulated where (a) the number of exacerbations per year increased progressively from 0 to 0.5, then 1, then 2 and eventually 3 exacerbations per year [33][34][35], and (b) each exacerbation caused an initial additional decline (-200 mL) which was a partially reversible decline in lung function (-175.5 mL) and which was reduced over 3 months to a smaller permanent decline (-24.5 mL), based on average data in the literature [3,14,36,37] (Supplementary Materials, Table S1). • COPD lung function decline is modified by pharmacotherapy. ...
... This finding is consistent with another study that enrolled sixty COPD patients and reported significantly higher mMRC score in the frequent exacerbator group. 21 Similarly, Cote et al. 22 reported higher mMRC scale in COPD patients with repeated AEs compared to those with a single exacerbation over a 24-month period. Our study provides further evidence supporting the predictive value of mMRC score for future severe exacerbations. ...
... When taking into account the insertions of the diaphragm, the lower thoracic compartment can be understood as a fixating compartment of respiratory movement. 27 There may be an increase in the recruitment and activation of non-diaphragmatic inspiratory muscles to compensate for this situation, which is understood as a mechanical disadvantage, since airway obstruction leads to a lowering of the diaphragm domes, which decreases the efficiency of this muscle. 16,23 The present findings lend support to these statements, as we found a greater contribution of the abdominal compartment, although without a significant increase in tidal volume. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/847288125632512-1579020639037_Q64/Juan-De-Torres.jpg)
... 3 The pathological changes associated with COPD result in persistent respiratory symptoms and progressive airflow obstruction, severely impacting patients' quality of life. 4 Although COPD is both preventable and treatable, 3 a combination of underdiagnosis and misdiagnosis often results in many patients receiving no or inappropriate treatment. This issue is critical given that the global prevalence of COPD is reported to be between 8.2% and 12.8%, a figure that is anticipated to rise owing to factors such as increased smoking and an ageing population. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272273424777254-1441926451699_Q64/Orlando-Diaz-3.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272665973882887-1442020042826_Q64/Carmen-Lisboa.jpg)
... A growing body of evidence suggests that sex differences exist in clinical manifestations and prognosis in stable COPD [23,24]. However, much less is known about any sex differences in characteristics, treatments and in-hospital clinical outcomes during AECOPD. ...
... Для определения ТФН у пациентов с ХОБЛ рекомендуется проведение нагрузочного тестирования, например, 6-минутного шагового теста (6-МШТ) или (в отдельных случаях) -велоэргометрии [28,29]. ...
... A number of previous studies have shown that high incidence of hypoxia in COPD patients could lead to a compensatory increase in erythropoietin (EPO), leading to secondary hyperhemoglobinemia. However, recent studies in China and abroad suggest that anemia was also one of the comorbidities of COPD and its incidence rate was even higher than that of hyperhemoglobinemia. 65,66 It was found that compared to hyperhemoglobinemia, anemia has a greater impact on the disease severity and quality of life in COPD patients. 67,68 As shown in a 9-year multicenter clinical study in Korea, anemia (WHO criteria) can serve as an independent risk factor for mortality in COPD. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/947282933477379-1602861259991_Q64/Marya-Zilberberg.jpg)
... Exacerbations are a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). They cause impaired health status and loss of exercise capacity [1,2]. Repeated exacerbations are associated with accelerated lung function and health status decline, and the number and severity of events are associated with increased all-cause mortality [3,4]. ...
... The 6-min walk distance is a strong predictor of outcomes for various lung diseases including IPF, COPD, sarcoidosis, and for group 1 pulmonary arterial hypertension [29][30][31][32][33]. It is also used as a common endpoint for clinical trials, pertinent to this patient population, such as the INCREASE trial, as well as in risk scores for COPD, including the BODE index [23,34]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/746973938343936-1555103873173_Q64/Victor-Pinto-Plata.jpg)
... We conducted 6-min walking-test (6MWT) in the study clinic, following European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines, expressed in metres (m), with a distance less than 350 m considered abnormal. 14,15 Lung function testing. We conducted on-site spirometry according to ERS/ATS guidelines 16 (EasyOne Connect PC software, Easy-On ultrasonic PC spirometer). ...
